Genprex announced that research from its sponsored collaboration with Meharry Medical College on TUSC2, the tumor suppressor gene in its lead oncology candidate REQORSA, will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting. The research investigates TUSC2's role in mitochondrial biology, cellular resilience, and molecular processes associated with aging. This work contributes to understanding REQORSA biology and may inform potential future therapeutic applications beyond oncology.

Artiva Biotherapeutics, Inc. announced it is halting all further development of AlloNK (AB-101) and initiating a process to explore strategic alternatives to maximize stockholder value. This includes a significant workforce reduction of approximately 94% of its current employee base. The company reported preliminary cash, cash equivalents, and investments of approximately $319.1 million as of September 30, 2026.

Genprex announced new peer-reviewed preclinical research on the TUSC2 gene, the therapeutic gene in its investigational REQORSA® gene therapy. The study in mice identified TUSC2's role in maintaining cellular processes associated with healthy brain aging, mitochondrial function, and protein homeostasis, with notable sex-specific differences. While REQORSA is developed for cancer, these findings broaden the scientific understanding of TUSC2's biological functions and suggest potential avenues for age-related cognitive disorders.

Caribou Biosciences is exploring strategic alternatives, including a potential merger or acquisition, to maximize stockholder value and has engaged Wedbush Securities Inc. as its financial advisor. Concurrently, the company is discontinuing further development of its allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (vispa-cel) and CB-011, which were in Phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, respectively. This restructuring includes a significant workforce reduction and is expected to incur $15 million to $19 million in related expenses.

Adagio Medical Holdings, Inc. is exploring strategic alternatives and, in connection with this process, lowered the conversion price of its 13% Senior Secured Convertible Notes. Between September 25 and October 1, 2026, a noteholder converted $776,111 in principal amount of these notes, resulting in the issuance of 4,978,869 shares of common stock at prices ranging from $0.1265 to $0.1618 per share. These shares were issued under an exemption from registration for exchanges of outstanding securities.

Adagio Medical Holdings, Inc. has initiated a process to explore a full range of strategic alternatives to enhance shareholder value, which may include M&A. Concurrently, the company is reducing its workforce by 25 out of 43 full-time employees, effective September 23, 2026, anticipating approximately $1.3 million in cash expenditures for severance and related costs. The company also lowered the conversion price for its 13% Senior Secured Convertible Notes to facilitate potential conversions during this period.

Karyopharm Therapeutics entered a Forbearance Agreement and issued $20 million in convertible preferred stock to certain lenders, aiming to gain time to advance its myelofibrosis program, negotiate with lenders, pursue strategic alternatives, or raise equity capital. The preferred stock includes repurchase rights that can be triggered by specific FDA actions or the company's withdrawal of its supplemental new drug application for selinexor in myelofibrosis.

Karyopharm Therapeutics entered into a forbearance agreement with its lenders and noteholders after defaulting on debt payments, providing the company until at least October 15, 2026, to negotiate with lenders, pursue strategic alternatives, or raise equity. The agreement also allows the company to advance its myelofibrosis program. As part of the agreement, Karyopharm will pay $20.0 million in fees by issuing convertible preferred stock, with the forbearance potentially terminating if the FDA refuses to accept its sNDA for selinexor in myelofibrosis.